Prolonged survival of end-stage AIDS patients immunized with therapeutic HIV vaccine V-1 Immunitor

Biomedicine and Pharmacotherapy

Volumn 59, Issue 8, 2005, Pages 469-473

  Metadilogkul, Orapun ^a   Jirathitikal, Vichai ^b   Bourinbaiar, Aldar S ^c  

^a Parasitol Trop Med Assoc T   (Thailand)

^b Bangpakong Industrial Park   (Thailand)

^c Immunitor USA Inc   (United States)

Author keywords

AIDS; Clinical endpoint; End stage; HAART; Immunotherapy; Life expectancy; Long term follow up; Morbidity; Mortality; Survival; Terminal stage; Therapeutic vaccine; Time to death

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG; V 1 IMMUNITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; HOSPICE CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOTHERAPY; KAPLAN MEIER METHOD; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; PALLIATIVE THERAPY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SURVIVAL; SURVIVAL TIME; TIME OF DEATH; TREATMENT OUTCOME; WILCOXON SIGNED RANKS TEST; WORLD HEALTH ORGANIZATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY, ACTIVE; MALE; PALLIATIVE CARE; SURVIVAL ANALYSIS; THAILAND;

EID: 25644444656     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2005.07.004     Document Type: Article

References (31)

1. S. Surasiengsunk, S. Kiranandana, K. Wongboonsin, G.P. Garnett, R.M. Anderson, and G.J. van Griensven Demographic impact of the HIV epidemic in Thailand AIDS 12 1998 775 784
2. D. Kitayaporn, S. Tansuphaswadikul, P. Lohsomboon, K. Pannachet, J. Kaewkungwal, and K. Limpakarnjanarat Survival of AIDS patients in the emerging epidemic in Bangkok, Thailand J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 11 1996 77 82
3. www.aidstemple.th.org.
4. A.S. Bourinbaiar, and V. Jirathitikal Low-cost anti-HIV compounds: potential application for AIDS therapy in developing countries Curr. Pharm. Des. 9 2003 1419 1431
5. V. Jirathitikal, and A.S. Bourinbaiar Safety and efficacy of an oral HIV vaccine (V-1 Immunitor) in AIDS patients at various stages of the disease HIV Clin. Trials 3 2002 21 26
6. 3 Acta Virol. 48 2004 73 78
7. A.S. Bourinbaiar, V. Jirathitikal, O. Metadilogkul, P. Sooksathan, S. Aemsri, and P. Promdevich Phase II placebo-controlled study of V-1 Immunitor as a therapeutic modality for treatment of HIV J. Clin. Virol. 31 2004 S55 S62
8. V. Jirathitikal, O. Metadilogkul, and A.S. Bourinbaiar Increased body weight and improved quality of life in AIDS patients following V-1 Immunitor administration Eur. J. Clin. Nutr. 58 2004 110 115
9. M.A. Egan Current prospects for the development of a therapeutic vaccine for the treatment of HIV type 1 infection AIDS Res. Hum. Retroviruses 20 8 2004 794 806
10. C.M. Tsoukas, J. Raboud, N.F. Bernard, J.S. Montaner, M.J. Gill, and A. Rachlis Active immunization of patients with HIV infection: a study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immunodeficiency AIDS Res. Hum. Retrovir. 14 1998 483 490
11. E. Sandstrom, and B. Wahren Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group Lancet 353 1999 1735 1742
12. J.O. Kahn, D.W. Cherng, K. Mayer, H. Murray, and S. Lagakos Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: a randomized controlled trial JAMA 284 2000 2193 2202
13. S. Schwander, M. Opravil, R. Luthy, D.G. Hanson, J. Schindler, and A. Dawson Phase I/II vaccination study of recombinant peptide F46 corresponding to the HIV-1 transmembrane protein coupled with 2.4 dinitrophenyl (DNP) Ficoll Infection 22 1994 86 91
14. C.E. Lindenburg, I. Stolte, M.W. Langendam, F. Miedema, I.G. Williams, and R. Colebunders Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression Vaccine 20 2002 2343 2347
15. O. Metadilogkul, V. Jirathitikal, and A.S. Bourinbaiar Survival of end-stage patients receiving V-1 Immunitor HIV Clin. Trials 3 2002 258 259
16. O. Rutschmann, and B. Hirschel Antiretroviral therapy: a guide to the most important trials Schweiz. Med. Wochenschr. 127 1997 436 443
17. M.D. Hughes, M.J. Daniels, M.A. Fischl, S. Kim, and R.T. Schooley CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group AIDS 12 1998 1823 1832
18. N.M. Graham, S.L. Zeger, L.P. Park, S.H. Vermund, R. Detels, and C.R. Rinaldo The effects on survival of early treatment of human immunodeficiency virus infection N. Engl. J. Med. 326 1992 1037 1042
19. J.D. Hamilton, P.M. Hartigan, M.S. Simberkoff, P.L. Day, G.R. Diamond, and G.M. Dickinson A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study N. Engl. J. Med. 326 1992 484 486
20. J. Darbyshire, M. Foulkes, R. Peto, W. Duncan, A. Babiker, and R. Collins Immediate versus deferred zidovudine (AZT) in asymptomatic or mildly symptomatic HIV infected adults Cochrane Database Syst. Rev. 2 2000 (CD002039)
21. A.N. Phillips, C. Katlama, S. Barton, S. Vella, A. Blaxhult, and B. Clotet Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 17 1998 239 244
22. M. Hirsch, R. Steigbigel, S. Staszewski, J. Mellors, E. Scerpella, and B. Hirschel A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy J. Infect. Dis. 180 1999 659 665
23. D.W. Cameron, M. Heath-Chiozzi, S. Danner, C. Cohen, S. Kravcik, and C. Maurath Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group Lancet 351 1998 543 549
24. S.M. Hammer, K.E. Squires, M.D. Hughes, J.M. Grimes, L.M. Demeter, and J.S. Currier A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team N. Engl. J. Med. 337 1997 725 733
25. C. Sabin Editorial comments HIV Clin. Trials 3 2002 259 260
26. L.P. Jacobson, A.J. Kirby, S. Polk, J.P. Phair, D.R. Besley, and A.J. Saah Changes in survival after acquired immunodeficiency syndrome (AIDS): 1984-1991 Am. J. Epidemiol. 138 1993 952 964
27. G.J. Ruiz-Arguelles, B. Lagunes-Yannelli, L. Mercado-Diaz, and D.D. Aleman-Hoey Survival of patients with advanced HIV infection treated with 300:mg/d of zidovudine: a prospective study Rev. Invest. Clin. 46 1994 491 493
28. F.A. Post, M. Badri, R. Wood, and G. Maartens AIDS in Africa - survival according to AIDS-defining illness S. Afr. Med. J. 91 2001 583 586
29. P. Mwaba, J. Mwansa, C. Chintu, J. Pobee, M. Scarborough, and S. Portsmouth Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions Postgrad. Med. J. 77 2001 769 773
30. A.S. Bourinbaiar, and R. Abulafia-Lapid Clinical experience with therapeutic AIDS vaccines. Expert Rev Vaccines 4 2005 289 3004
31. V. Jirathitikal, P. Sooksathan, O. Metadilogkul, and A.S. Bourinbaiar V-1 Immunitor: oral therapeutic AIDS vaccine with prophylactic potential Vaccine 21 2003 624 628